Guest Post: Policy conditions make or break leaders in biopharmaceutical innovation: Preliminary results from the 2017 BCI Survey
By Guest Contributor | July 24, 2017
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
A critical opportunity to prevent prescription drug abuse
By Anne McDonald Pritchett, PhD | June 2, 2017
U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb recently cited addressing the opioid crisis as his highest priority. As someone who has spent the bulk of my career focused on...
Read More
340B Spotlight: 340B hospitals continue to benefit from consolidation at expense of patients
By Rebecca Davison | April 27, 2017
As we’ve noted before, incentives to profit under the 340B program are leading to an uneven playing field for providers and may be shifting care to more expensive and less convenient settings in...
Read More
Australia is making it harder to protect inventions. That’s bad for American businesses and jobs.
By Jay Taylor | April 25, 2017
Bringing a single new medicine to market requires substantial resources over many years. To ensure continued investment in the development of tomorrow’s breakthrough treatments and cures,...
Read More
Trading fair means upholding the law: A focus on patents
By Jay Taylor | April 18, 2017
Patents are the linchpin of innovation. In the United States and other countries around the world, they provide temporary protection for new inventions. A fair, stable and predictable patent...
Read More
Enforcing unmet trade obligations protects U.S. innovation
By Jay Taylor | April 11, 2017
The United States leads the world in medical innovation, helping patients across the globe access the latest life-saving treatments and cures. Trade agreements with other nations serve as the...
Read More
Stakeholders Agree: Modernize the legal framework to support move to value-driven health care
By Michelle Drozd | March 6, 2017
Modernizing certain laws and regulations to support the move to value-driven health care is an important step in moving our health care system forward. As part of PhRMA’s proactive policy...
Read More
How do multiple sclerosis patients define value?
By Lauren Neves | February 24, 2017
There are crucial conversations occurring in the health care system about how value is defined. To explore how multiple sclerosis (MS) patients, providers and payers view value, Real Endpoints...
Read More
The Value Collaborative: Advancing private market solutions to achieve better health, lower costs
By Stephen J. Ubl | January 31, 2017
Each day, biopharmaceutical researchers push the bounds of medical science to find new treatments and cures to the most complex conditions facing patients. The launch of GOBOLDLY™, our new...
Read More
ICER glosses over significant progress in MS treatment
By Holly Campbell | November 30, 2016
Multiple sclerosis (MS) is a devastating chronic autoimmune disease that can affect a person’s brain, spinal cord and optic nerves, causing problems with vision, balance, muscle control and other...
Read More
Medicare Monday (100)
340B Spotlight (33)
Cost & Consequence (0)
